Dr. Yaron Hadari

Dr. Yaron Hadari co-founded SHY Therapeutics in 2015 to explore his hypothesis, since proven by SHY, that the Kd of GTP binding to Ras is in a druggable range. He has served as Chief Executive Officer and Chief Scientific Officer since the company’s inception.

Prior to forming SHY, Dr. Hadari served as Vice President of Research at Kolltan Pharmaceuticals, where he led efforts to develop monoclonal antibody cancer therapies and worked with Mr. Schmertzler. Before his tenure at Kolltan, he was Senior Director of the Cell Biology Department at ImClone Systems (acquired by Eli Lilly), overseeing early and late-stage monoclonal antibody cancer therapy programs.

In his academic career, Dr. Hadari focused on the biological roles of receptor tyrosine kinases and related signal transduction pathways.

Dr. Hadari holds an M.S. and Ph.D. from the Weizmann Institute of Science and a B.Sc. from the Hebrew University.